https://m2.mtmt.hu/ hun 2026-10-24 10:52 JournalArticle 35257351 VALIDATED true Department of Medical Oncology, Szent Margit Hospital, Budapest, 1032, Hungary Department of Programming Languages and Compilers, Faculty of Informatics, Eötvös Loránd University (ELTE), Budapest, 1117, Hungary Department of Oncoradiology, Bács-Kiskun County Hospital, Kecskemét, 6000, Hungary Department of Thoracic and Abdominal Tumors and Clinical Pharmacology, National Institute of Oncology, Budapest, 1122, Hungary Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, 1122, Hungary National Tumor Biology Laboratory, Budapest, 1122, Hungary Department of Oncology, Semmelweis University, Budapest, 1122, Hungary Export Date: 22 July 2025; Cited By: 0; Correspondence Address: G. Rubovszky; Department of Thoracic and Abdominal Tumors and Clinical Pharmacology, National Institute of Oncology, Budapest, 1122, Hungary; email: garub@oncol.hu 0 false 2026-06-08T10:01:47.338+0000 2025-11-13T10:11:28.900+0000 2024-09-11T07:24:51.170+0000 true 10034203 Kaposi Ambrus /api/author/10034203 Author Kaposi Ambrus (Típuselmélet) true 10034203 2025-12-03T12:38:23.944+0000 2025-12-03T12:38:23.944+0000 2025-01-23T14:40:02.312+0000 true 10029372 Szabó Tibor /api/admin/10029372 Admin Szabó Tibor (ELTE IK admin 5) true 10029372 2025-11-13T10:11:29.106+0000 true 10029372 Szabó Tibor /api/admin/10029372 Admin Szabó Tibor (ELTE IK admin 5) true 10029372 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Boér, Katalin true true /api/journal/10032813 REVIEWED CANCERS 2072-6694 true false 10032813 false 10032813 true 2072-6694 Journal FOREIGN 16 17 2928 2928 13 2024 The use of the Oncotype DX test reduces the rate of adjuvant chemotherapy recommendations. Few in-depth analyses have been performed on this decision-making process.We retrospectively analyzed patient data based on available Oncotype DX test results (RS) irrespective of nodal status at a single center. We collected recommendations from six oncologists, first without RS (pre-RS) and then with RS results (post-RS). We investigated changes in recommendations, agreement between oncologist decisions, and the effect of different National Comprehensive Cancer Network (NCCN) recommendation categories (for, against, and considering chemotherapy).Data from 201 patients were included in the analysis. Recommendation of chemotherapy decreased by an average of 39.5%. Agreement improved substantially with RS, with a kappa value pre-RS of 0.37 (fair agreement) and post-RS of 0.75 (substantial agreement). Discordance remained substantial in cases where the NCCN recommendations considered chemotherapy only (32%). Pre-RS consensus against chemotherapy predicted low RS results (50 out of 51 patients). Post-RS consensus was highest in the NCCN chemotherapy recommendation group.The Oncotype DX test substantially improves decision accuracy in recommending adjuvant chemotherapy. It may be further improved with a consensus decision. In the case of pre-RS consensus against chemotherapy, the test can be spared. Funding 2044238 /api/funding/2044238 (2020-4.1.1.-TKP2020-MOLOKRIV) false true Funding 2044239 /api/funding/2044239 (SE HUN-REN-TKI ENDOMOLPAT) false true Funding 2044240 /api/funding/2044240 (K128780) Támogató: Nemzeti Kutatás, Fejlesztés és Innovációs Iroda false true true true 2024 true true true false true false GOLD 2026-06-08 true https://edit.elte.hu/xmlui/handle/10831/121045 1 0 1 1 0 1 1 1 0 1 1 1 1 1 0 0 1 1 1 1 0 1 1 Folyóiratcikk Journal Article 24 1 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2026 0 1 1 1 1 Q1 false false false false 2024-09-24T08:10:42.267+0000 Onkológiai Tanszék (SE / AOK / K); Országos Onkológiai Intézet; Programozási Nyelvek és Fordítóprogramok Tanszék (ELTE / IK) 7 36 3 8 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 119270029 /api/authorship/119270029 Boér, Katalin [Boér, Katalin (Klinikai Orvostud...), szerző] 1 0.125 true false false Author 10048974 /api/author/10048974 Boér Katalin (Klinikai Orvostudomány) Boér Katalin true 10048974 true Boér Katalin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 119270030 /api/authorship/119270030 Kaposi, Ambrus [Kaposi, Ambrus (Típuselmélet), szerző] Programozási Nyelvek és Fordítóprogramok Tanszék (ELTE / IK) 2 0.125 false false false Author 10034203 /api/author/10034203 Kaposi Ambrus (Típuselmélet) Kaposi Ambrus true 10034203 true Kaposi Ambrus true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 119270031 /api/authorship/119270031 Kocsis, Judit [Kocsis, Judit (Onkológia, belgyó...), szerző] 3 0.125 false false false Author 10023831 /api/author/10023831 Kocsis Judit (Onkológia, belgyógyászat) Kocsis Judit true 10023831 true Kocsis Judit true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 119810201 /api/authorship/119810201 Horváth, Zsolt [Horváth, Zsolt (Onkológia), szerző] Országos Onkológiai Intézet 4 0.125 false false false Author 10026959 /api/author/10026959 Horváth Zsolt (Onkológia) Horváth Zsolt true 10026959 true Horváth Zsolt true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 119270033 /api/authorship/119270033 Madaras, Balázs 5 0.125 false false false Madaras Balázs true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 119270034 /api/authorship/119270034 Sávolt, Ákos [Sávolt, Ákos (emlősebész), szerző] Országos Onkológiai Intézet 6 0.125 false false false Author 10072975 /api/author/10072975 Sávolt Ákos (emlősebész) Sávolt Ákos true true Sávolt Ákos true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 119270035 /api/authorship/119270035 Klément, György Benjamin [Klément, György Benjámin (Onkológia), szerző] Országos Onkológiai Intézet 7 0.125 false false false Author 10097219 /api/author/10097219 Klément György Benjámin (Onkológia) Klément György Benjámin true true Klément György Benjamin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 119270036 /api/authorship/119270036 Rubovszky, Gábor ✉ [Rubovszky, Gábor (klinikai onkológia), szerző] Országos Onkológiai Intézet; Onkológiai Tanszék (SE / AOK / K) 8 0.125 false true true Author 10060070 /api/author/10060070 Rubovszky Gábor (klinikai onkológia) Rubovszky Gábor true 10060070 true Rubovszky Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 27153147 /api/publicationidentifier/27153147 DOI: 10.3390/cancers16172928 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/cancers16172928 https://doi.org/10.3390/cancers16172928 false true PublicationIdentifier 27539418 /api/publicationidentifier/27539418 WoS: 001311118200001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001311118200001 https://www.webofscience.com/wos/woscc/full-record/001311118200001 false true PublicationIdentifier 32475929 /api/publicationidentifier/32475929 EDIT: 121045 SwordSource 92 /api/publicationsource/92 EDIT PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true EDIT EDIT https://edit.elte.hu/xmlui/handle/10831/@@@ true true 92 true GREEN true 121045 https://edit.elte.hu/xmlui/handle/10831/121045 false true PublicationIdentifier 27539417 /api/publicationidentifier/27539417 Scopus: 85203654809 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85203654809 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85203654809 false true PublicationIdentifier 27283414 /api/publicationidentifier/27283414 PubMed: 39272786 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39272786 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39272786&dopt=Abstract false true SjrRating 11488787 /api/sjrrating/11488787 sjr:Q1 (2024) Scopus - Oncology CANCERS 2072-6694 86 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2730 /api/classificationexternal/2730 Scopus - Oncology true 2730 true Q1 DIRECT true true Reference 57255145 /api/reference/57255145 1. Bray 2024: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries., CA Cancer J. Clin., 74, p. 229, DOI: 10.3322/caac.21834 1 10.3322/caac.21834 false true Reference 57255146 /api/reference/57255146 2. Loibl 2024: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann. Oncol., 35, p. 159, DOI: 10.1016/j.annonc.2023.11.016 2 10.1016/j.annonc.2023.11.016 false true Reference 57255147 /api/reference/57255147 3. Li, G.Q., Xie, S.J., Wu, S.G., and He, Z.Y. (2023). Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes. Front. Endocrinol., 14., DOI: 10.3389/fendo.2023.1103949 3 10.3389/fendo.2023.1103949 false true Reference 57255148 /api/reference/57255148 4. Licata 2023: Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer., NPJ Breast Cancer, 9, p. 51, DOI: 10.1038/s41523-023-00559-6 4 10.1038/s41523-023-00559-6 false true Reference 57255149 /api/reference/57255149 5. Swain 2024: A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009., J. Clin. Oncol., 42, p. TPS612, DOI: 10.1200/JCO.2024.42.16_suppl.TPS612 5 10.1200/JCO.2024.42.16_suppl.TPS612 false true Reference 57255150 /api/reference/57255150 6. Sparano 2018: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer., N. Engl. J. Med., 379, p. 111, DOI: 10.1056/NEJMoa1804710 6 10.1056/NEJMoa1804710 false true Reference 57255151 /api/reference/57255151 7. Kalinsky 2021: 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer., N. Engl. J. Med., 385, p. 2336, DOI: 10.1056/NEJMoa2108873 7 10.1056/NEJMoa2108873 false true Reference 57255152 /api/reference/57255152 8. Fleiss 1971: Measuring nominal scale agreement among many raters., Psychol. Bull., 76, p. 378, DOI: 10.1037/h0031619 8 10.1037/h0031619 false true Reference 57255153 /api/reference/57255153 9. McHugh 2012: Interrater reliability: The kappa statistic., Biochem. Medica, 22, p. 276, DOI: 10.11613/BM.2012.031 9 10.11613/BM.2012.031 false true Reference 57255154 /api/reference/57255154 10. National Comprehensive Cancer Network (2024, February 01). Breast Cancer (Version 1.2024). Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. 10 false true Reference 57255155 /api/reference/57255155 11. Dank 2020: Az emlőrák szisztémás kezelése: Szakmai irányelvek [Systemic treatment of breast cancer: Professional guideline]., Magy. Onkológia, 64, p. 348 11 false true Reference 57255156 /api/reference/57255156 12. R. Core Team (2023). A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, R. Core Team. Available online: https://www.R-project.org/. 12 false true Reference 57255157 /api/reference/57255157 13. Wu 2024: Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races., Clin. Breast Cancer, 24, p. e61, DOI: 10.1016/j.clbc.2023.10.005 13 10.1016/j.clbc.2023.10.005 false true Reference 57255158 /api/reference/57255158 14. Orucevic 2019: Nomogram update based on TAILORx clinical trial results—Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data., Breast, 46, p. 116, DOI: 10.1016/j.breast.2019.05.006 14 10.1016/j.breast.2019.05.006 false true Reference 57255159 /api/reference/57255159 15. Humphris 2021: Predicting oncotype DX recurrence scores using locally available immunohistochemical markers: Experience in a district general hospital., J. Clin. Pathol., 76, p. 252, DOI: 10.1136/jclinpath-2021-207934 15 10.1136/jclinpath-2021-207934 false true Reference 57255160 /api/reference/57255160 16. Baltres 2020: Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer., Breast Cancer., 27, p. 1007, DOI: 10.1007/s12282-020-01100-4 16 10.1007/s12282-020-01100-4 false true Reference 57255161 /api/reference/57255161 17. Thibodeau 2019: Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor., Hematol. Oncol. Stem Cell Ther., 12, p. 89, DOI: 10.1016/j.hemonc.2019.02.001 17 10.1016/j.hemonc.2019.02.001 false true Reference 57255162 /api/reference/57255162 18. Levine 2016: Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario., J. Clin. Oncol., 34, p. 1065, DOI: 10.1200/JCO.2015.62.8503 18 10.1200/JCO.2015.62.8503 false true Reference 57255163 /api/reference/57255163 19. Kapadia 2020: Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?., Breast J., 26, p. 2199, DOI: 10.1111/tbj.14068 19 10.1111/tbj.14068 false true Reference 57255164 /api/reference/57255164 20. Crager 2022: Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer., Breast Cancer Res., 24, p. 74, DOI: 10.1186/s13058-022-01571-7 20 10.1186/s13058-022-01571-7 false true Reference 57255165 /api/reference/57255165 21. Saigosoom 2020: The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy., Cancer Manag. Res., 12, p. 2491, DOI: 10.2147/CMAR.S237423 21 10.2147/CMAR.S237423 false true Reference 57255166 /api/reference/57255166 22. Glasgow 2021: Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: A single institutional review., Breast Cancer, 28, p. 321, DOI: 10.1007/s12282-020-01163-3 22 10.1007/s12282-020-01163-3 false true Reference 57255167 /api/reference/57255167 23. Slembrouck 2021: Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer., Mod. Pathol., 34, p. 1297, DOI: 10.1038/s41379-021-00743-8 23 10.1038/s41379-021-00743-8 false true Reference 57255168 /api/reference/57255168 24. Alkushi 2021: The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings., Cureus, 13, p. e13298 24 false true Reference 57255169 /api/reference/57255169 25. Albanell 2016: Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer., Eur. J. Cancer, 66, p. 104, DOI: 10.1016/j.ejca.2016.06.027 25 10.1016/j.ejca.2016.06.027 false true Reference 57255170 /api/reference/57255170 26. Soliman, H., Shah, V., Srkalovic, G., Mahtani, R., Levine, E., Mavromatis, B., Srinivasiah, J., Kassar, M., Gabordi, R., and Qamar, R. (2020). MammaPrint guides treatment decisions in breast Cancer: Results of the IMPACt trial. BMC Cancer, 20., DOI: 10.1186/s12885-020-6534-z 26 10.1186/s12885-020-6534-z false true Reference 57255171 /api/reference/57255171 27. Morales 2015: Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative earlystage breast cancer., Curr. Med. Res. Opin., 31, p. 1129, DOI: 10.1185/03007995.2015.1037730 27 10.1185/03007995.2015.1037730 false true Reference 57255172 /api/reference/57255172 28. Lo 2010: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection., J. Clin. Oncol., 28, p. 1671, DOI: 10.1200/JCO.2008.20.2119 28 10.1200/JCO.2008.20.2119 false true Reference 57255173 /api/reference/57255173 29. Oratz 2011: Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer., J. Oncol. Pract., 7, p. 94, DOI: 10.1200/JOP.2010.000046 29 10.1200/JOP.2010.000046 false true Reference 57255174 /api/reference/57255174 30. Dieci 2019: Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study., Oncologist, 24, p. 1424, DOI: 10.1634/theoncologist.2019-0103 30 10.1634/theoncologist.2019-0103 false true Reference 57255175 /api/reference/57255175 31. Kuchel 2016: The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: A prospective study., Br. J. Cancer, 114, p. 731, DOI: 10.1038/bjc.2016.48 31 10.1038/bjc.2016.48 false true Reference 57255176 /api/reference/57255176 32. Wuerstlein 2019: WSG-PRIMe investigators in Germany, Austria, Switzerland. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: Results of the WSG-PRIMe study., Breast Cancer Res. Treat., 175, p. 389, DOI: 10.1007/s10549-018-05075-x 32 10.1007/s10549-018-05075-x false true Reference 57255177 /api/reference/57255177 33. Kwiatkowski 2020: Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14)., Breast, 49, p. 132, DOI: 10.1016/j.breast.2019.10.013 33 10.1016/j.breast.2019.10.013 false true Reference 57255178 /api/reference/57255178 34. Cheng, R., Kong, X., Wang, X., Fang, Y., and Wang, J. (2020). Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database. Front. Oncol., 10., DOI: 10.3389/fonc.2020.01583 34 10.3389/fonc.2020.01583 false true Reference 57255179 /api/reference/57255179 35. Crolley 2020: The impact of Oncotype DX breast cancer assay results on clinical practice: A UK experience., Breast Cancer Res. Treat., 180, p. 809, DOI: 10.1007/s10549-020-05578-6 35 10.1007/s10549-020-05578-6 false true Reference 57255180 /api/reference/57255180 36. Iles 2022: The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment., NPJ Breast Cancer, 8, p. 27, DOI: 10.1038/s41523-022-00394-1 36 10.1038/s41523-022-00394-1 false true Reference 57255181 /api/reference/57255181 37. McSorley 2024: Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland., Curr. Oncol., 31, p. 1302, DOI: 10.3390/curroncol31030098 37 10.3390/curroncol31030098 false true Reference 57255182 /api/reference/57255182 38. Efe 2022: Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands., Int. J. Breast Cancer, 2022, p. 5909724 38 false true Reference 57255183 /api/reference/57255183 39. 40. Andre, F., Ismaila, N., Allison, K.H., Barlow, W.E., Collyar, D.E., Damodaran, S., Henry, N.L., Jhaveri, K., Kalinsky, K., and Kuderer, N.M. (2022). Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J. Clin. Oncol., 40, 1816–1837., DOI: 10.1200/JCO.22.00069 39 10.1200/JCO.22.00069 false true Reference 57255184 /api/reference/57255184 40. Pece 2022: Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy., Eur. J. Cancer, 164, p. 52, DOI: 10.1016/j.ejca.2022.01.003 40 10.1016/j.ejca.2022.01.003 false true /api/publication/35257351 Boér Katalin et al. How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer. (2024) CANCERS 2072-6694 16 17<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10048974"><a href="/gui2/?type=authors&mode=browse&sel=10048974" target="_blank">Boér Katalin (<span class="authorship-author-name">Boér Katalin</span> <span class="authorAux-mtmt"> Klinikai Orvostudomány</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10034203"><a href="/gui2/?type=authors&mode=browse&sel=10034203" target="_blank">Kaposi Ambrus (<span class="authorship-author-name">Kaposi Ambrus</span> <span class="authorAux-mtmt"> Típuselmélet</span>) </a> </span> <span class="author-affil"><span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Informatikai Kar">IK</span>/<span title="Informatikatudományi Intézet">Informtud_I</span>/Programozási Nyelvek és Fordítóprogramok Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023831"><a href="/gui2/?type=authors&mode=browse&sel=10023831" target="_blank">Kocsis Judit (<span class="authorship-author-name">Kocsis Judit</span> <span class="authorAux-mtmt"> Onkológia, belgyógyászat</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10026959"><a href="/gui2/?type=authors&mode=browse&sel=10026959" target="_blank">Horváth Zsolt (<span class="authorship-author-name">Horváth Zsolt</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Madaras Balázs </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10072975"><a href="/gui2/?type=authors&mode=browse&sel=10072975" target="_blank">Sávolt Ákos (<span class="authorship-author-name">Sávolt Ákos</span> <span class="authorAux-mtmt"> emlősebész</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10097219"><a href="/gui2/?type=authors&mode=browse&sel=10097219" target="_blank">Klément György Benjamin (<span class="authorship-author-name">Klément György Benjámin</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10060070"><a href="/gui2/?type=authors&mode=browse&sel=10060070" target="_blank">Rubovszky Gábor ✉ (<span class="authorship-author-name">Rubovszky Gábor</span> <span class="authorAux-mtmt"> klinikai onkológia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Onkológiai Tanszék</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35257351" target="_blank">How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer</a></div> <div> <span class="journal-title">CANCERS</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2072-6694">2072-6694</a>)</span>: <span class="journal-volume">16</span> <span class="journal-issue">17</span> <span class="page"> Paper 2928. 13 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/cancers16172928" target="_blank" href="https://doi.org/10.3390/cancers16172928"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001311118200001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001311118200001"> WoS </a> </span> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:black" title="121045" target="_blank" href="https://edit.elte.hu/xmlui/handle/10831/121045"> EDIT </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85203654809" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85203654809"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="39272786" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39272786&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cancer Research&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 1</span> | Független: 1 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 1 | WoS/Scopus jelölt:&nbsp;1 | DOI jelölt:&nbsp;1 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35257351&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 1 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35257351</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (2020-4.1.1.-TKP2020-MOLOKRIV), (SE HUN-REN-TKI ENDOMOLPAT), (K128780) Támogató: NKFIH </div> <div class="lastModified">Utolsó módosítás: 2025.11.13. 11:11 Szabó Tibor (ELTE IK admin 5) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Department of Medical Oncology, Szent Margit Hospital, Budapest, 1032, Hungary Department of Programming Languages and Compilers, Faculty of Informatics, Eötvös Loránd University (ELTE), Budapest, 1117, Hungary Department of Oncoradiology, Bács-Kiskun County Hospital, Kecskemét, 6000, Hungary Department of Thoracic and Abdo...</pre> </div></div>